Jacquelyn Pence, Michelle Stockton, Richard J. Bloomer*

Pence et al. J Clin Transl Res 2023; 9(3):3

Published online: April 26, 2023


Background and aim: Joint pain afflicts millions of adults worldwide. The effect of a Bone Morphogenetic Protein Complex on joint pain is assessed in this study.
Methods: We compared the impact of a dietary supplement protein complex (Cyplexinol®) and placebo in 18 men and women (aged 43±10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg per day). Subjects completed questionnaires (e.g., WOMAC and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (TNF-α, IL-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures.
Results: Pain and discomfort scores improved (p≤0.05) for subjects following use of Cyplexinol® but not placebo. Improvements were noted for WOMAC pain (p=0.05), stiffness (p=0.039), and total pain (p=0.026), as well as VAS pain (p=0.015), recreational activity interference (p=0.023), mood interference (p=0.012), and total pain (p=0.024). A trend was noted for WOMAC physical function (p=0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol® (p=0.01), with a similar increase noted for placebo (p=0.022). A near doubling in TGF-β (p=0.001) was noted for Cyplexinol®. No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (p>0.05).
Conclusions: Cyplexinol® can alleviate joint pain in middle-aged men and women, while elevating BMP5. Cyplexinol® does not influence cytokines, at least within a short two-week supplementation period or within the two-hour post-ingestion period.
Relevance for Patients: Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol®, as we observed decreased pain and stiffness following treatment.


DOI: http://dx.doi.org/10.18053/jctres.09.202303.003

Author affiliation

Center for Nutraceutical and Dietary Supplement Research, College of Health Sciences, University of Memphis, Memphis, TN, United States of America

*Corresponding author
Richard J. Bloomer
Center for Nutraceutical and Dietary Supplement Research, College of Health Sciences, University of Memphis, 106 Elma Roane Fieldhouse, Memphis, TN 38152, Memphis, TN, United States of America.
Tel: +1 901 678 5638
Email: rbloomer@memphis.edu

Handling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Chemistry, Utrecht University, Utrecht, the Netherlands
Department of Pathology, Erasmus Medical Center, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China


Full text PDF